The Bacterial Conjunctivitis drugs in development market research report provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bacterial Conjunctivitis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued products.

GlobalData tracks six drugs in development for Bacterial Conjunctivitis by six companies/universities/institutes. The top development phase for Bacterial Conjunctivitis is preclinical with three drugs in that stage. The Bacterial Conjunctivitis pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bacterial Conjunctivitis pipeline products market are: NTC, TaeJoon Pharmaceuticals and Cellics Therapeutics.

The key targets in the Bacterial Conjunctivitis pipeline products market include DNA Topoisomerase IV (EC, DNA Gyrase (EC, and DNA Primase (EC

The key mechanisms of action in the Bacterial Conjunctivitis pipeline product include DNA Topoisomerase IV (EC Inhibitor with two drugs in Phase II. The Bacterial Conjunctivitis pipeline products include six routes of administration with the top ROA being Ophthalmic and two key molecule types in the Bacterial Conjunctivitis pipeline products market including Small Molecule, and Biologic.

Bacterial Conjunctivitis overview

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light, and burning eyes. Treatment includes antibiotics.

For a complete picture of Bacterial Conjunctivitis’s pipeline drug market, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.